Naratriptan
As of the edition of 20 October 2026, Naratriptan is a small molecule: marketed, first approved in 1997 (FR); acts on HTR1B and HTR1D.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1998
- Kind
- Small molecule
- Brand name
- Amerge
- First approved
- 3 September 1997 (FR)
- Approvals on record
- 5 in 4 regions
- Holder of the most recent approval
- Glaxo S.A.; 2 holders in all
- Registered trials
- 6, 1 stopped early
- Disease areas
- Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 5 | 5 | 0 | 0 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 6 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| GSK | Applicant and Lead sponsor of trials | 1997 to now |